Beyond the Lab: How One Founder Harnessed AI to Conquer His Cancer Diagnosis

Conno Christou, a 35-year-old founder building his second company, was meticulously dialed-in on his health, tracking sleep with a Whoop band and Oura ring, and undergoing annual biomarker checks. Following protocols from longevity researchers like Peter Attia and Rhonda Patrick, his 2025 checkup was "green across the board," marking his best health in years.

However, an unexpected arm swelling after a workout led to the discovery of two blood clots. During pre-op exams for the clots, doctors found an 11-by-11-by-8 centimeter mass behind his sternum. A biopsy confirmed an aggressive, fast-growing form of non-Hodgkin’s lymphoma – a rare genetic mutation with no connection to lifestyle, diet, or stress. The tumor had developed in only three months and was just weeks away from reaching stage four, making Christou "lucky in his unluckiness" that it was found incidentally.

Facing this critical diagnosis, Christou encountered conflicting medical advice. His first oncologist, a renowned specialist, recommended a lighter chemotherapy regimen with a 60% success rate. Seeking a second opinion the night before his scheduled infusion, another doctor strongly advised a harder, continuous in-hospital infusion regimen, citing Christou’s specific pathology, which offered an 85% success rate. Recognizing this significant divergence, Christou, adopting a founder's mindset, gathered a total of 12 opinions from hematologists and oncologists globally, leveraging his professional network. Eleven of the twelve specialists endorsed the more aggressive treatment path, a decision Christou viewed as logical rather than brave, given his data-driven nature and the existential stakes.

Throughout the six months of treatment, Christou approached chemotherapy like building a company: a "marathon of sprints," each with a finite cycle and weekly data points. Drawing on his mandatory military service experience, he committed to being a "good soldier," trusting the process through six cycles. He continued using his Whoop band, finding it remarkably accurate in predicting immune system troughs before symptoms appeared. He meticulously logged every shift, side effect, and medication using voice transcription in a symptom journal. His focus narrowed to three critical variables: sleep, nutrition, and, most importantly, psychology. He affirmed that psychology "moves the needle more than anything," noting he "never asked ‘why me’ — not once," recognizing the lack of a useful answer to such a question.

A pivotal aspect of Christou’s journey was his utilization of AI, specifically Claude. He fed all his medical data – blood results, scan data, wearable output, and journal entries – into the chatbot. While acknowledging that AI "didn’t replace the doctors," Christou emphasized its role in helping him "ask the right questions," especially for a condition as rare as his. He found that access to a model trained on the full body of medical literature provided insights superior to a standard Google search, offering a depth of information an oncologist might only encounter once a year.

The AI proved indispensable at the conclusion of his treatment when his final PET scan, used to detect active disease, returned an ambiguous result. His oncologist began discussing a potential second line of therapy, including radiotherapy near his heart and lungs. Alarmed, Christou researched and discovered a startling 60% false-positive rate on end-of-treatment PET scans for his specific lymphoma, a statistic he found astonishing for 2026. He submitted all three of his PET scans and his MRI into Claude, which then flagged a known, yet easily overlooked, phenomenon: in patients under 40 recovering from this type of lymphoma, the thymus gland can reactivate after chemotherapy, mimicking active disease on imaging. Based on his age and specific scan characteristics, the model estimated a 90% probability of thymus rebound. Seeking three more opinions, a fourth doctor confirmed the diagnosis: thymus rebound. There was no active disease, and no radiotherapy was needed; he was clear.

Reflecting on the past year, Christou is still processing its profound impact on his health, work, and perspective on time. He founded Keragon, an AI-powered platform for automating medical administrative operations, before his diagnosis. However, experiencing the medical system as a patient offered new insights, revealing how nurses and doctors are often overwhelmed by non-care tasks. He observed receiving the same chemotherapy protocol as an 80-year-old woman, with side effects managed by a cascade of additional drugs, each with its own problems. He believes future generations will "cringe" at this era of treatment. Now, he prioritizes taking Sundays off and being present in his life, cherishing moments with friends and his dog, and finding importance in the advice from a VC friend: "Be happy now." Conno Christou openly offers to connect with anyone undergoing similar experiences, emphasizing that AI’s transformative potential for patients is "not happening in 10 years" but "happening today."